Detailed information for compound 1671404

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 442.48 | Formula: C19H24F2N4O4S
  • H donors: 1 H acceptors: 4 LogP: 1.28 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: C=CC(=O)Nc1ccc(cc1)S(=O)(=O)N1CCN(CC1)C(=O)N1CCC(CC1)(F)F
  • InChi: 1S/C19H24F2N4O4S/c1-2-17(26)22-15-3-5-16(6-4-15)30(28,29)25-13-11-24(12-14-25)18(27)23-9-7-19(20,21)8-10-23/h2-6H,1,7-14H2,(H,22,26)
  • InChiKey: XMNBZHULQOIYJP-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens coagulation factor XIII, A1 polypeptide Starlite/ChEMBL References
Homo sapiens transglutaminase 2 Starlite/ChEMBL References
Homo sapiens transglutaminase 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Onchocerca volvulus Get druggable targets OG5_131468 All targets in OG5_131468
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Mycobacterium ulcerans transglutaminase family protein 0.0129 0.3205 0.5
Mycobacterium leprae Conserved hypothetical protein 0.0129 0.3205 0.5
Echinococcus granulosus geminin 0.0191 0.5178 1
Echinococcus multilocularis geminin 0.0191 0.5178 1
Brugia malayi MH2 domain containing protein 0.0135 0.3381 1
Plasmodium falciparum ataxin-2 like protein, putative 0.0028 0 0.5
Mycobacterium ulcerans putative transglutaminase-like protein 0.0129 0.3205 0.5
Giardia lamblia Transglutaminase/protease, putative 0.0129 0.3205 0.5
Plasmodium falciparum ataxin-2 like protein, putative 0.0028 0 0.5
Mycobacterium ulcerans hypothetical protein 0.0129 0.3205 0.5
Mycobacterium ulcerans hypothetical protein 0.0129 0.3205 0.5
Mycobacterium leprae Conserved hypothetical protein 0.0129 0.3205 0.5
Mycobacterium tuberculosis Conserved hypothetical protein 0.0129 0.3205 0.5
Toxoplasma gondii LsmAD domain-containing protein 0.0028 0 0.5
Mycobacterium tuberculosis Hypothetical protein 0.0129 0.3205 0.5
Loa Loa (eye worm) transcription factor SMAD2 0.0135 0.3381 1
Leishmania major hypothetical protein, conserved 0.0028 0 0.5
Loa Loa (eye worm) MH2 domain-containing protein 0.0135 0.3381 1
Trichomonas vaginalis peptide N-glycanase, putative 0.0129 0.3205 0.5
Mycobacterium tuberculosis Long conserved protein 0.0129 0.3205 0.5
Plasmodium vivax ataxin-2 like protein, putative 0.0028 0 0.5
Trypanosoma cruzi PAB1-binding protein , putative 0.0028 0 0.5
Mycobacterium tuberculosis Conserved hypothetical protein 0.0129 0.3205 0.5
Schistosoma mansoni hypothetical protein 0.0191 0.5178 1
Giardia lamblia Hypothetical protein 0.0129 0.3205 0.5
Schistosoma mansoni hypothetical protein 0.0191 0.5178 1
Trypanosoma brucei PAB1-binding protein , putative 0.0028 0 0.5
Brugia malayi Thioredoxin family protein 0.0129 0.3205 0.9479
Mycobacterium tuberculosis Conserved protein 0.0129 0.3205 0.5
Trypanosoma cruzi PAB1-binding protein , putative 0.0028 0 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.041 uM Inhibition of human recombinant TG2 by fluorescent transamidation assay ChEMBL. 22224594
IC50 (binding) = 0.31 uM Inhibition of thrombin activated human F13a by fluorescent transamidation assay ChEMBL. 22224594
IC50 (binding) = 0.81 uM Inhibition of human TG2 in HEK cells by fluorescent transamidation assay ChEMBL. 22224594
IC50 (binding) = 5.4 uM Inhibition of human recombinant TG1 by fluorescent transamidation assay ChEMBL. 22224594
IC50 (binding) > 80 uM Inhibition of thrombin activated human TG3 by fluorescent transamidation assay ChEMBL. 22224594
Ratio IC50 (binding) = 20 Ratio of IC50 to human TG2 in HEK cells to IC50 for human recombinant TG2 ChEMBL. 22224594

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.